<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04390529</url>
  </required_header>
  <id_info>
    <org_study_id>IRMA</org_study_id>
    <nct_id>NCT04390529</nct_id>
  </id_info>
  <brief_title>Immediate Breast Reconstruction Following Mastectomy (IRMA)</brief_title>
  <acronym>IRMA</acronym>
  <official_title>A Multicenter, Observational Cohort Study of Women Undergoing Immediate Breast Reconstruction Following MAstectomy (IRMA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thurgau Breast Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thurgau Breast Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on data from the US Surveillance, Epidemiology and End Result Program (SEER), the rates&#xD;
      of nipple-sparing mastectomy (NSM) have risen 202% since 2009. In spite of the increasing&#xD;
      popularity of IRMA, limited research has been done to identify complications in patients&#xD;
      undergoing these procedures. Of particular importance is to assess the effects of combining&#xD;
      the procedure with radiotherapy, and undergoing a one- versus two-step surgical procedure.&#xD;
&#xD;
      Active monitoring and periodic assessment of IRMA patients are needed to establish the safety&#xD;
      of these different techniques in terms of complications and recurrence rates. Identifying an&#xD;
      optimal strategy for IRMA may lead to the development of clinical guidelines, which are&#xD;
      currently lacking.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter observational, cohort study. The study is designed to serve a similar&#xD;
      purpose as a disease registry. The only study-specific intervention will be the completion of&#xD;
      the BREAST-Q quality-of-life (QoL) form. Only quantitative data will be collected. The&#xD;
      rationale for this study design is to identify and describe the type and frequency of&#xD;
      complications related to IRMA. No hypothesis is being tested. Although group comparisons&#xD;
      based on surgical techniques will be made, conclusions based on these findings will be&#xD;
      limited by the observational nature of the design.&#xD;
&#xD;
      Data from patients will be collected using a series of pseudonymized case report forms,&#xD;
      including the validated quality-of-life questionnaire: BREAST-Q. These data will be entered&#xD;
      into the web-based data collection system, SecuTrial. A precise description of the surgical&#xD;
      procedure will be required, as specified on the case report forms (e.g., implantation of a&#xD;
      mesh, resection margins), to allow for subsequent multivariate analyses.&#xD;
&#xD;
      During the first year of follow-up, data from routine clinical assessments and the QoL forms&#xD;
      will be gathered at baseline (within 90 days after mastectomy), 6 and 12 months. Thereafter,&#xD;
      data will be collected from annual clinical assessments and completion of the QoL form will&#xD;
      be done for an additional four years (24, 36, 48 and 60 months postoperatively).&#xD;
      Consequently, a total of five years of postoperative follow-up data will be collected to&#xD;
      allow sufficient time for the development of the majority of foreseeable complications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of nipple-areola complex (NAC) or skin flap necrosis requiring specific treatment/surgery</measure>
    <time_frame>Three years after surgery</time_frame>
    <description>Postoperative follow-up assessments include the documentation of nipple-areola complex (NAC) or skin flap necrosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of infection requiring surgery</measure>
    <time_frame>Three years after surgery</time_frame>
    <description>Postoperative follow-up assessments include the documentation of infections requiring surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade of surgical complications</measure>
    <time_frame>Three years after surgery</time_frame>
    <description>Postoperative follow-up assessments include the documentation of surgical complications (grading according to Clavien-Dindo Classification of Surgical Complications)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of minor complications not requiring surgery</measure>
    <time_frame>Three years after surgery</time_frame>
    <description>Postoperative follow-up assessments include the documentation of skin necrosis outside NAC, wound dehiscence, and seroma requiring drainage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of patient satisfaction with cosmesis</measure>
    <time_frame>Five years after surgery</time_frame>
    <description>Postoperative follow-up assessment using BREAST-Q quality-of-life questionnaire that measures patient satisfaction with cosmetic outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of sensitivity of the operated breast (NAC) compared to the non-operated breast</measure>
    <time_frame>Five years after surgery</time_frame>
    <description>Postoperative follow-up assessments of breast functional outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of breast cancer recurrence</measure>
    <time_frame>Five years after surgery</time_frame>
    <description>Postoperative follow-up assessments include the documentation of recurrence in the NAC, skin flap outside the NAC, chest wall, locoregional lymph node (axillary, supraclavicular), distant metastasis</description>
  </secondary_outcome>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Breast Cancer Female</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>quality-of-life questionnaire: BREAST-Q</intervention_name>
    <description>quality-of-life questionnaire: BREAST-Q</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women undergoing IRMA (NSM: nipple-areola sparing mastectomy or SSM: skin-sparing&#xD;
        mastectomy) at any participating breast center may be included in the study. Patients&#xD;
        undergoing IRMA for either prophylactic or oncologic purposes are eligible.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any women ≥ 18 years of age undergoing IRMA (NSM or SSM) at any participating breast&#xD;
             center may be included in the study.&#xD;
&#xD;
          -  Women undergoing IRMA for either prophylactic or oncologic purposes&#xD;
&#xD;
          -  Enrolment is possible up to 90 days after mastectomy&#xD;
&#xD;
          -  A patient who has had the mastectomy at a non-participating institution, but has&#xD;
             subsequently sought treatment at one of the study centers, may be eligible for&#xD;
             enrolment up to 90 days following mastectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwillingness to have follow-up assessments at the participating breast centers&#xD;
&#xD;
          -  Limited ability to understand study-specific procedures, which includes language&#xD;
             difficulties.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Breast cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Mathias Fehr, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brustzentrum Thurgau, Kantonsspital Frauenfeld</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mathias Fehr, Prof. Dr.</last_name>
    <phone>0041 52 723 72 55</phone>
    <email>mathias.fehr@stgag.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>JoEllen Welter, MPH</last_name>
    <phone>0041 52 723 72 56</phone>
    <email>joellen.welter@stgag.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kantonsspital Baden, PD Dr. med. Cornelia Leo</name>
      <address>
        <city>Baden</city>
        <state>Aargau</state>
        <zip>5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christin Kiesewetter</last_name>
      <phone>0041 56 486 36 36</phone>
      <email>Gynstudien@ksb.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brustzentrum Bern Biel, Hirslanden</name>
      <address>
        <city>Bern</city>
        <state>BE</state>
        <zip>3013</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrizia Sager, Dr.</last_name>
      <email>Patrizia.Sager@hirslanden.ch</email>
    </contact>
    <contact_backup>
      <last_name>Silvia Andrist</last_name>
      <phone>0041 31 337 89 69</phone>
      <email>Silvia.Andrist@hirslanden.ch</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre du Sein de Genève - Hirslanden Clinique des Grangettes</name>
      <address>
        <city>Chêne-Bougeries</city>
        <state>GE</state>
        <zip>1224</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Patricia Brunelli Roche, Dr.</last_name>
      <email>patricia.brunelli@bluewin.ch</email>
    </contact>
    <contact_backup>
      <last_name>Ashley Machen</last_name>
      <phone>0041 22 545 28 73</phone>
      <email>ashley.machen@grangettes.ch</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Tumor- und Brustzentrum ZeTuP, Dr. Véronique Dupont Lampert</name>
      <address>
        <city>St. Gallen</city>
        <state>Saint Gallen</state>
        <zip>9006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolette Hoefnagels, MSc</last_name>
      <phone>0041 71 243 0227</phone>
      <email>nicolette.hoefnagels@zetup.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brustzentrum Ostschweiz</name>
      <address>
        <city>St. Gallen</city>
        <state>SG</state>
        <zip>9016</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rahel Hiltebrand, Dr.</last_name>
      <phone>0041 71 552 33 33</phone>
      <email>rahel.hiltebrand@bz-ost.ch</email>
    </contact>
    <contact_backup>
      <last_name>Claudia Frey</last_name>
      <email>Claudia.Frey@bz-ost.ch</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Frauenfeld, Prof. Dr. med. Mathias K. Fehr</name>
      <address>
        <city>Frauenfeld</city>
        <state>Thurgau</state>
        <zip>8500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JoEllen Welter, MPH</last_name>
      <phone>0041 52 723 72 56</phone>
      <email>joellen.welter@stgag.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale Bellinzona e Valli, Dr. Begoña Lipp von Wattenwyl</name>
      <address>
        <city>Bellinzona</city>
        <state>Ticino</state>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Begoña Lipp von Wattenwyl, Dr.</last_name>
      <phone>0041 91 811 9438</phone>
      <email>BegonaMaria.LippVonWattenwyl@eoc.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spital Wetzikon</name>
      <address>
        <city>Wetzikon</city>
        <state>ZH</state>
        <zip>8620</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Beck, Dr.</last_name>
      <email>denise.beck@gzo.ch</email>
    </contact>
    <contact_backup>
      <last_name>Marta Bachmann</last_name>
      <phone>0041 44 934 28 49</phone>
      <email>marta.bachmann@gzo.ch</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Brust Centrum Zürich, Bethanien &amp; Zollikerberg</name>
      <address>
        <city>Zollikerberg</city>
        <state>ZH</state>
        <zip>8125</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hisham Fansa, Prof. Dr.</last_name>
      <email>hisham.fansa@spitalzollikerberg.ch</email>
    </contact>
    <contact_backup>
      <last_name>Irene Brenneisen</last_name>
      <phone>0041 44 397 24 01</phone>
      <email>irene.brenneisen@spitalzollikerberg.ch</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Stadtspital Triemli</name>
      <address>
        <city>Zürich</city>
        <state>ZH</state>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heike Passmann, Dr.</last_name>
      <phone>0041 44 416 11 11</phone>
      <email>Heike.Passmann@triemli.zuerich.ch</email>
    </contact>
    <contact_backup>
      <last_name>Barbara Herzog</last_name>
      <email>Barbara.Herzog@triemli.zuerich.ch</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Campus SLB Sonnenhof AG</name>
      <address>
        <city>Bern</city>
        <zip>3001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves Brühlmann, Dr.</last_name>
      <phone>0041 31 309 95 30</phone>
      <email>yves.bruehlmann@plast.ch</email>
    </contact>
    <contact_backup>
      <last_name>Cindy Groen</last_name>
      <email>cindy.groen@lindenhofgruppe.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Gilles Berclaz, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Zürich, Klinik für Gynäkologie</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heike Frauchiger-Heuer, Dr.</last_name>
      <phone>0041 44 255 52 00</phone>
      <email>heike.frauchiger-heuer@usz.ch</email>
    </contact>
    <contact_backup>
      <last_name>Isabel Breyer</last_name>
      <email>Isabel.breyer@usz.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

